Clinical trials: Uveitis, Intermediate
Uveitis
Daclizumab and Sirolimus to Treat Uveitis
This study will examine whether the combination of the drugs daclizumab and sirolimus can effectively treat adults with uveitis, an eye inflammation.
- Trial name
- NCT00078689
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Uveitis, Intermediate Uveitis
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE-2 (NCT01280669)
- Testing
- Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg
- Where
- United States
- Sponsor
- Stanford University
Uveitis
Psychosocial Outcomes and Transition Readiness in Uveitis
It is widely acknowledged that the transition from paediatric to adult health services should be a multidimensional and multidisciplinary process that addresses the medical, psychosocial, and educational needs of adolescents and…
- Trial name
- NCT03554824
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- Sheffield Children's NHS Foundation Trust
Uveitis, Intermediate, Macular Edema
Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
The purpose of this study is to investigate if interferon beta is superior to the standard treatment with Methotrexate for the treatment of intermediate uveitis and macular edema.
- Conditions
- Uveitis, Intermediate, Macular Edema, Multiple Sclerosis
- Trial name
- NCT00344253
- Testing
- Interferon beta, Methotrexate
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Heidelberg University
Trematode Induced Granulomatous Uveitis
Vitrectomy Versus Suprachoroidal Steroid in Trematodal Granulomatous Uveitis
Presumed trematode-induced granulomatous intermediate uveitis (PTIGIU) presents with vitritis and complicated cataract (active stage) which, if left untreated, progresses to tractional retinal detachment (TRD) from the…
- Trial name
- NCT07105072
- Testing
- Vitrectomy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Minia University
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Background: Uveitis is a serious inflammatory condition that affects the eye and can cause vision loss. A common secondary problem associated with uveitis is macular edema (swelling).
- Trial name
- NCT00943982
- Testing
- Interferon Gamma 1-b
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Uveitis, Uveitis, Posterior
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- TYNI (NCT05486468)
- Testing
- Yutiq 0.18 MG Drug Implant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Texas Retina Associates
Non Infectious Uveitis
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU).
- Trial name
- PEACOCX (NCT07427628)
- Testing
- TRX103
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Quan Dong Nguyen
Uveitis
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Background: Uveitis is an inflammation of the eye that can cause vision loss. It is treated with medications and sometimes surgery. However, in many people, treatment does not always prevent loss of vision.
- Trial name
- NCT02911116
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Eye Institute (NEI)
Uveitis
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity.
- Trial name
- NCT05384249
- Testing
- Izokibep
- Where
- 69 sites in United States, Austria and 5 more
- Volunteers
- 96 people
- Sponsor
- ACELYRIN Inc.
Non-infectious Uveitis
Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and…
- Trial name
- CHRONOS (NCT05928754)
- Testing
- care strategy
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Intermediate Uveitis, Posterior Uveitis
Retisert and Cataract Surgery in Patients With Severe Uveitis
To review chart data at the Duke Eye Center and determined whether a 3-year fluocinolone acetonide sustained drug delivery system (FA) safely suppressed postoperative inflammation when combined with phacoemulsification and…
- Trial name
- NCT00570830
- Testing
- Retisert (fluocinolone acetonide implant)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Uveitis
Multicenter Uveitis Steroid Treatment (MUST) Trial
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis…
- Trial name
- MUST (NCT00132691)
- Testing
- fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 255 people
- Sponsor
- JHSPH Center for Clinical Trials
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Posterior, Uveitis, Intermediate
Ozurdex Monotherapy Trial
This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- OM (NCT05101928)
- Testing
- Ozurdex 0.7mg Ophthalmic Implant, Prednisone
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Non-infectious Intermediate, Posterior and Panuveitis
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
- Trial name
- NCT03339102
- Where
- 17 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- AbbVie
Behcet's Disease, Uveitis
Immunogenetic Mechanisms in Behcet's Disease
Background: Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year.
- Trial name
- NCT01109433
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Eye Institute (NEI)